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ABSTRACT
Background: Accelerometers are accurate tools to assess movement and physical activity. However, inter-
preting standardly used outputs is not straightforward for populations with impaired mobility.
Methods: The applicability of GENEActiv was explored in a group of 30 participants with myotonic dys-
trophy and compared to a group of 14 healthy-controls. All participants performed a set of tests while
wearing four different accelerometers (wrists and ankles): [1] standing still; [2] ten-meters walk test; [3] six-
minutes walking test; and, [4] ten-meters walk/run test.
Results: Relevant findings were: [1] high intra-accelerometer reliability (i.e. 0.97 to 0.99; p< 0.001); [2]
each test acceleration values differ significantly between each other; [3] no inter-accelerometer reliability
between wrist-worn devices and ankle-worn; and [4] a significant difference between the myotonic dys-
trophy group and the healthy-controls detectable at each test (i.e. Left-ankle values at six-minutes walking
test: 48±17 for the myotonic dystrophy group, vs, 74±16 for the healthy-controls; p< 0.001).
Conclusions: GENEActiv demonstrated to be valid and reliable, capable of detecting walking periods and dis-
criminating different speeds. However, inter-accelerometer reliability only applied when comparing opposite
sides of the same limb. Specific movement characteristics of the myotonic dystrophy group were identified
and muscle strength showed not to be a full determinant of limb acceleration.
 IMPLICATIONS FOR REHABILITATION
 Rehabilitation professionals in the field of neuromuscular disorders should be aware of the potential
use of objective monitoring tools such as accelerometers whilst acknowledging the implications of
assessing populations with altered movement patterns.
 Researchers should be cautious when translating accelerometry outputs previously validated in
healthy populations to functionally impaired cohorts like myotonic dystrophy.
 Accelerometers can objectively expose movement disturbances allowing further investigations for the
source of these disturbances.
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Introduction
In recent years, accelerometers have been proposed as accurate and
sensitive tools to assess movement patterns, physical activity inten-
sity, daily life activity behaviour and sleep in healthy and disabled
populations [1,2]. Accelerometer outputs derive from detecting and
recording body acceleration and deceleration over specific periods of
time that can later be transformed into meaningful outputs such as
energy expenditure or step counts [3]. This type of technology has
increasingly been implemented to investigate diseases with impaired
mobility including neuromuscular disorders [4–6]. However, the
majority of these more clinically meaningful outputs are obtained
from validation studies using healthy individuals and the translation
to diseased or physically impaired individuals is not that straightfor-
ward and requires further validations [7,8].
Myotonic Dystrophy type 1 (DM1) is a rare autosomal domin-
ant neuromuscular disorder, which affects multiple organ systems
resulting in signs of premature ageing, muscle weakness, myo-
tonia and fatigue among other symptoms [9,10]. This is the most
common inherited muscular dystrophy amongst adults encom-
passing about 30% of genetic caused neuromuscular disorder in
this age group [11]. Muscle weakness, regardless of having a rela-
tively slow progression, has proven to impact significantly on
patient’s ambulation and balance, most particularly the ankle
weakness [12,13]. The combination of muscle weakness and the
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fatigue and daytime sleepiness, results in a population less active
and with reduced social participation [14,15]. There is no current
drug on market available for these patients so alternative methods
to improve patient’s quality of life have been proposed [16].
Targeting DM1 disturbed physical activity patterns has been pro-
posed as a possible method to combat fatigue and increase daily
life participation [17,18].
Activity monitors (including accelerometers) may help to (1) deter-
mine whether altered activity behaviours are present in this cohort
independent of time and location of the probands; (2) establish an
ideal dose of physical activity required to impact on specific health
parameters; (3) set measurable goals for activity-related interventions;
and (4) establish a surrogate outcome measure for therapies that
promise an improvement in patient’s mobility and performance
[19–21]. To optimally apply these tools we first must understand their
usability in the target population. The purpose of this study was to
compare accelerometry data between a DM1 cohort and healthy
controls. To explore the reliability of their use to detect ambulation
at different speeds; and finally, to assess which body location (wrist
or ankle), if any, is better to place these devices when measuring
ambulation in the DM1 population.
Methods
Participants
The DM1 group was recruited from an on-going DM1 natural history
study in the United Kingdom (PHENODM1 study). This sub-study
included 30 adult genetically confirmed DM1 patients who were
recruited to one of the sites (Royal Victoria Infirmary – Newcastle
Upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United
Kingdom) and assessed at baseline only. All DM1 participants provided
written informed consent and completed the functional assessments
independently (walking assistive devices and orthosis were permitted).
The matched healthy-control group consisted of 14 adult participants
from Newcastle University, Newcastle upon Tyne, United Kingdom.
The study protocol was approved by the Newcastle and North
Tyneside Ethics committee (Ref: NE/15/0178) and the Newcastle
University Ethics committee (Ref: 5572/2016). All procedures performed
in the study were in accordance with the Declaration of Helsinki.
For sub-group analysis, the DM1 group participants were classi-
fied as mild (i.e., late onset) if they met two of the three following
criteria as assessed at baseline: (1) first symptoms reported at the
age of 40 or older; (2) 200 or fewer repeats of the CTG nucleoid
triplet (i.e., genotype severity); and (3) a score of 1 or 2 on the
Muscular Impairment Rating Scale [22]. The rest were categorized
as classic (i.e., adult onset) phenotype [23].
Study assessments
All participants wore four accelerometers at the same time: one on
each limb (right wrist, right ankle, left wrist and left ankle) while per-
forming different functional assessments following pre-established
standardized operational procedures. Functional assessments per-
formed were (1) stand still for a minimum of 10 s; (2) 6min walking
test (6MWT) [24]; (3) 10 m walking test (10-mWT), where patients
were requested to walk at their comfortable speed [25]; and (4) 10 m
walk/run test (10-mW/RT), where patients were requested to walk as
fast as possible and if considered capable, running was allowed [25];
and all followed this same sequential order. With these functional
assessments, we aimed to elicit participants’ individual walking paces
with 10-mWT representing selected (i.e., comfortable) pace, 6MWT
representing fast walking pace and 10-mW/RT representing the fastest
possible pace (including running). 10-mWT and 10-mW/RT were
performed three times with a brief rest in between each test until
participant’s reported recovery. MicroFet-2 in standardized testing
positions was used to assess isometric strength of the DM1 group
for the following muscles: ankle dorsiflexors, knee extensors and
hip flexors.
Accelerometer
The GENEActiv (Activinsights Ltd., Cambridgeshire, United
Kingdom) tri-axial accelerometer was utilized in this study, which
can be worn on multiple body locations such as the wrist, ankle
or hip. Wrist-worn GENEActiv data have demonstrated strong val-
idity against indirect calorimetry for both physical activity and
sedentary behaviour [26,27]. Accelerometer data was processed in
R (www.cran.r-project.org) using R-package [28]. The output metric
(i.e., unit) used was Euclidean Norm Minus One – miligravitational
units (ENMO – mg), which not only considers the acceleration in
three planes provided by the device but also systematically
includes gravity into its algorithm (as in (x2þ y2 þ z2)1/2 – 1) mak-
ing it more reliable for dynamic physical activity estimations
[29–31]. Prior to testing, all devices were configured equally to
their maximum sampling frequency of 100Hz.
Data extraction
Data extracted were converted into 1-s epochs (counts) and
then imported into a custom-built Excel spread sheet that
included a column for time (h:min:s) and a column for the
acceleration value (ENMO – mg) registered at each second.
Based on the assessor’s records, start and finish timings for
each of the functional tasks and the closest 10 s were plotted
to identify the real start point as the point with a visible incre-
ment in acceleration value and continued until the recorded
finish time. For each functional set of data, the mean units per
second was calculated and then multiplied by 60 to obtain a
value per minute for each task [32].
Statistical analysis
Gaussian distribution was tested for each individual set of data using
Shapiro–Wilk test. For our initial aim, mean acceleration values per
minute from each performed test were compared between the DM1
and the healthy-controls groups using Mann-Whitney U Test.
We performed a multivariate analysis of covariance (MANCOVA)
adjusted by sex (male/female) and age (years) to corroborate if any
differences were influenced by any of these factors.
To test the second and third aims, intra-class correlation coeffi-
cient (ICC) were estimated between accelerometers to assess
inter-accelerometer reliability and Bland-Altman plots were used
to examine the agreement level between the different body loca-
tions of the accelerometers (i.e., ankle versus wrist, right-ankle ver-
sus left-ankle and right-wrist versus left-wrist) [33,34]. Spearman’s
correlation coefficients (rho) were also calculated for each func-
tional test comparing accelerometry units per second with the
results from each performed test (i.e., distance and speed) and
muscle strength (i.e., myometry). All statistical analyses were per-
formed using SPSS version 23 (IBM Corporation, Armonk, NY) and
only results with p values0.05 were considered as statistically
significant for discussion and conclusion matters.
Results
The demographic variables show a Gaussian distribution for both
groups (i.e., DM1 and healthy-controls), hence data were treated
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accordingly. Participants’ characteristics are presented in Table 1.
There was an age difference between groups and in the total of
meters completed for the 6MWT.
Regardless of the accelerometer placement site, mean acceler-
ation values at each individual task differ significantly between
DM1 and healthy-controls at both ankle and wrist reports with
the exception of the times considered as standing still (Table 2).
In the walking tests, the results from the wrist demonstrated
closer or mildly overlapping 95% confidence interval between the
DM1 group and the healthy-controls group, which was not the
case for the ankle data (see Table 2). The average acceleration
detected when walking at a comfortable pace (10-mWT) and at a
sub-maximal pace (6MWT) were higher in the ankle devices than
in the wrist devices for both groups. When fastest pace was tested
(10-mW/RT), the wrist-worn accelerometers detected the higher
scores in the healthy-controls group, but not in the DM1 (Figure
1(a,b)). However, when the DM1 participants were sub-divided
into mild (n¼ 7) and classic (n¼ 23) phenotypes (refer to meth-
ods), the mild-sub-group showed the same pattern as the healthy
participants, but not for the more severe (classic) phenotype
(Figure 1(c)). With the exception of the left wrist worn accelerom-
eter at the 10-mWT (Table 2), the MANCOVA did not show any
changes on the significance levels when adjusting by sex nor age.
When comparing accelerometers within themselves (i.e., intra-
accelerometer ICC) values ranged from 0.86 (95% CI 0.74–0.93,
p¼ 0.003; DM1 cohort during the 10-mWT) to 0.97 (95% CI
0.95–0.99, p< 0.001; DM1 during the 6MWT) for the walking tests.
During the running test (i.e., 10-mW/RT), intra-accelerometer reli-
ability was higher (p¼) for the DM1 cohort (0.96; 95% CI
0.93–0.98, p< 0.001) than for the healthy controls (0.76; 95% CI
0.38–0.93, p< 0.001). By comparing the values obtained from each
limb between each other inter-accelerometer reliability was esti-
mated. Both groups (i.e., DM1 and healthy-controls) presented
similar result patterns. There was no agreement between devices
placed in the wrist when compared to those placed in the ankle
at neither of the performed tasks. For example, the coefficient
estimated for the left-wrist accelerometer against left-ankle one
during the 6MWT was of 0.59 (95% CI 0.12 to 0.88, p< 0.001).
Devices on the same body location but opposite sides presented
good reliability (i.e., ICC>0.8) for all performed tasks with the
exception of left-wrist versus right-wrist when standing still
(ICC¼ 0.62; 95% CI 0.53 to 0.9, p< 0.001). However, the confi-
dence interval of the mean agreement got wider at faster speeds
more obvious on the healthy-controls group. For example, the
coefficient estimated between left-ankle and right-ankle during
the 6MWT was 0.98 (95% CI 0.93–0.99, p< 0.001) and for the 10-
mW/RT was 0.85 (95% CI 0.45–0.96, p¼ 0.004).
Bland–Altman plots between ankle and wrist measurements
were estimated identifying differences between the mean values
that invalidated the plots for all tests except running. On the
valid-to-perform plots (i.e., ankle versus wrist 10-mW/RT), the
higher the acceleration value the further the mean value will
appear from the estimated agreement level.
Correlation analysis showed stronger correlation values
between the 6MWT distance completed and the ankle-worn accel-
erometry units (mean ENMO per minute) (Table 3). There was no
correlation identified in the DM1 group for the wrist-worn devices
and all correlation values were higher on the healthy-controls
group. Correlation analysis between lower limb muscle strength
and accelerometry demonstrated the following: the relationship
between strength and acceleration increases in parallel with the
increment of walking speed. Walking at a comfortable speed (i.e.,
10-mWT) did not show any correlation with accelerometry.
Whereas the 10-mW/RT showed a moderate correlation with: knee
extensors (r¼ 0.4, p¼ 0.05) and hip flexors (r¼ 0.43, p¼ 0.02); and,
border line significance with ankle dorsiflexors (r¼ 0.4, p¼ 0.06).
Discussion
This study explored the usability of a tri-axial accelerometer
(GENEActiv, Activinsights, Cambridgeshire, United Kingdom) in
short walking tests in DM1 participants in comparison with a
healthy cohort. ICC estimations showed an excellent level of
agreement within each accelerometer for all walking distances val-
idating the accuracy of this technology for an ambulant DM1
population in accordance with findings in other study populations
and protocols [35]. However, the accelerometer location impacts
significantly when translating raw data into meaningful outputs.
An inter-accelerometer reliability was proven when comparing
accelerometers of the same limbs between each other (i.e., oppos-
ite sides) but not when comparing different limbs (i.e., wrist and
ankle). This reliability was reduced with the increment of speed
when it is expected that the arms will increase their force to
accelerate over the legs (i.e., running test). This is a common case
scenario with accelerometers as these devices can exhibit a phe-
nomenon where a speed increment could either emphasize walk-
ing disturbances that reflect differences between the limbs or
enhance a frequency-dependent filtering effect of accelerometers
where the amplitude of the acceleration waves lose priority over fre-
quency [36–38]. These findings strongly confirm that algorithms cre-
ated for activity outputs validated for the wrist cannot be translated
directly onto the ankle. This applies for either healthy or disease pop-
ulations. When reporting activity outputs derived from accelerometry,
Table 2. Mean acceleration units for each performed task presented by group.
DM1 Healthy-controls
Task Location Mean (95% CI) Mean (95% CI) Sig.
Stand Still Left wrist 2.3 (1.53.2) 2.7 (1.54.0) 0.26
Right wrist 2.3 (1.73.0) 2.5 (1.43.4) 0.65
Left ankle 1.2 (0.71.7) 1.9 (0.73.1) 0.40
Right ankle 1.3 (0.81.7) 1.7 (0.62.7) 0.30
10-mWT Left wrist 13.2 (11.814.6) 17 (13.520.5) 0.03a
Right wrist 12.1 (10.913.3) 18.1 (13.023.2) 0.001
Left ankle 37.4 (33.841.0) 46.0 (41.850.2) 0.001
Right ankle 37.6 (34.240.9) 48.1 (41.954.3) 0.001
6MWT Left wrist 21.3 (15.527.1) 40.6 (27.553.7) < 0.001
Right wrist 20.3 (15.225.5) 41.9 (26.357.4) 0.002
Left ankle 47.6 (41.553.7) 74.4 (65.183.8) < 0.001
Right ankle 47.8 (41.654.0) 75.5 (66.484.7) < 0.001
10-mW/RT Left wrist 99.3 (66.8131.8) 210.6 (189.5231.6) < 0.001
Right wrist 94 (62.8125.3) 214.9 (188.0241.9) < 0.001
Left ankle 101.6 (82.1121.1) 183.6 (160.9206.3) < 0.001
Right ankle 98.1 (80.9115.3) 176.5 (155.0198.1) < 0.001
Walking tests are presented from slow to fast: 10-mWT (10 m walk test), 6MWT
(6min walking test), 10-mW/RT (10 m walk/run test).
aWhen adjusted to age and gender the significance level changed to 0.08 and
estimated marginal means of 16.7 for healthy controls and 13.4 for the DM1
group. 95% CI (95% confidence interval for mean).
Table 1. Demographic characteristics of study sample presented by group. Data
are presented as mean values or scores (standard deviation).
DM1 Healthy-controls
N (N¼males) 30 (20) 14 (6)
Age – years (min–max) 48 (25–72) 32 (23–47)a
Height – cm (SD) 171 (8) 168 (11)
BMI (SD) 25 (5) 24 (4)
6MWT (m) 440 (147) 685 (82)a
BMI: body mass index (weight/height2); 6MWT: 6-min walking test; SD: stand-
ard deviation.
aDifference between groups is statistically significant (sig< 0.001).
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researchers have to be aware of the origin of these outputs and
when the applicability of the source is questionable it is recom-
mended to better present direct accelerometry units.
GENEActiv (Activinsights, Cambridgeshire, United Kingdom)
demonstrated potential when assessing different walking speeds
in this disease cohort and showed sensitivity to differentiate the
affected from non-affected and a difference in range values
between walking speeds. However, no difference was reported in
the standing-still position. This device was also sensitive enough
to notice variances between disease phenotypes (i.e., classic and
mild). The findings in Table 2 provided evidence that each device
recorded higher acceleration with each activity intensity increment
and that these values differed from slower walkers (e.g., DM1) to
faster walkers. The proximity observed in the 95% confidence
interval estimated for the wrist values when walking might sug-
gest the ankle as a better option to distinguish walking periods of
a DM1 participant with a comfortable speed, detecting outputs
between 33 and 41 ENMO (mg)/min (i.e., acceleration units).
Average acceleration per minute detected at the ankle differed
significantly from the wrist when walking and this difference dis-
appeared when increasing speed into running. However, this
effect is less evident in the DM1 cohort. This can certainly be
explained by an impaired running capability, which agrees with
the differences observed within the DM1 cohort when the sample
was sub-divided into mild and classic phenotypes (Figure 1).
At present, the 6MWT is the most commonly used outcome
measure in NMD in assessing functionality and fitness [39]. The
Figure 1. Box plots representing the accelerometer reports for each test per limb-placement. (a) The 10-m walking at comfortable pace test (10-mWT); and (b) the 10-
m walk/run test (10-mW/RT) which implies the fastest pace performed. (c) The DM1 group sub-divided into classic and mild phenotypes (classification explained in
methods). Values on the y-axis represent the average of acceleration (ENMO-mg) per minute for each test. Values on the x-axis showed the two groups tested: DM1
and healthy controls.
Table 3. Spearman’s (rho) correlation values estimated between total distance
(m) completed during the 6-min walking test (6MWT) and each of the acceler-
ometer units reports (ENMO per minute).
Accelerometer
location DM1 Healthy-controls
Whole
sample
Left Wrist 0.14 0.62 0.46
Right Wrist 0.16 0.63 0.46
Left Ankle 0.38 0.86 0.65
Right Ankle 0.42 0.78 0.68
p< 0.05; p< 0.01 (correlation significance).
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performance on the 6MWT depends on factors such as limb
strength, joints mobility, balance and cardiovascular fitness, all of
which will influence directly or indirectly on the limb power and
range of motion when performing the test [40,41]. In this present
study, when 6MWT was correlated to the accelerometry data pro-
vided by each different accelerometer, there was an overall higher
correlation with the ankle devices and was certainly more signifi-
cant in the case of the DM1 group as these showed no correlation
with what was reported by the wrist-worn devices. The higher val-
ues observed on the healthy-controls could indicate that in the
case of the DM1 participants there are additional factors influenc-
ing on their 6MWT performance besides the speed of their limbs
when walking.
When exploring relationships of accelerometry with lower limb
strength, there were only moderate correlation scores, which were
actually not consistent along all tests. This may reflect the small
sample size (n¼ 30). However, when considering the scores identi-
fied as statistically significant and the point that there was a min-
imal relationship detected at comfortable speed these suggest the
relevance of other disease-factors (not muscle strength) that may
impact on walking speed (i.e., balance, fatigue or motivation). Due
to the importance of walking, investigating other factors interfer-
ing with its speed will be highly relevant.
A common and more reliable placement site for accelerome-
ters has been the waist [42,43]. However, distal joints have shown
better compliance by participants which is an advantage when
considering them for clinical trials [42,44]. From these two place-
ment-options, this is not the first time that ankle has been sug-
gested as the most appropriate site for placing an accelerometer
as it has been identified before as the most effective when aiming
to classify different speeds in activity, in particular to distinguish
low-speed walkers and when recognizing activities such as ambu-
lation and cycling [44–46]. Important to emphasize is that this
conclusion might not apply in two relevant cases: (1) for energy
expenditure predictions as these are influenced by a range of
other factors such as heart rate and oxygen consumption [30,47];
and (2) at detecting non-ambulant activities of daily life living
such as gardening, housework or recreational activities [48]. Few
studies in other populations have suggested that thigh and ankle-
worn devices may have a higher correlation to actual physical
activity energy expenditure [47,49,50]. A crucial need in this sec-
tion is the identification of intensity thresholds for the ankle that
can differentiate the movements recorded as inactive (sedentary),
low, moderate or vigorous activity-intensities and all these should
be estimated for the targeted population specifics. Additionally,
research on the use of these devices on other body parts such as
hip or tight is still relevant as these locations might reduce the
impact of distal weakness and may be more reliable when assess-
ing sedentary periods [51,52].
When considering GENEActiv for a clinical trial, the overall dif-
ferences between wrist-worn and ankle-worn accelerometer
results might not be significant enough to force for one location
over the other [48] and the location-selection should be guided
by the main research question, protocol particular characteristics
and specifics of the targeted sample [53]. Already, the first
randomized controlled trial in DM1 selected the use of GENEActiv
in the ankle and the ENMO-mg units measure as a secondary out-
come measure to assess the impact of their intervention on the
physical activity levels of the patients [18]. One limitation of this
study is that only one metric methodology was used (i.e.,
“classical” accelerometer measures used for activity assessment)
[29–31]. Implementing other methods of analysis or signal proc-
essing may change the perspective. Still, the high-resolution data
collected in this study would allow such investigations to be con-
ducted in the future.
Conclusions
When interpreting results from an activity monitor used in a func-
tionally impaired population caution is needed as the majority of
these outputs might come from validation studies performed with
healthy volunteers. This study provided evidence that disturbances
observed in diseased cohorts such as DM1 might impact significantly
on results. The body location of the device impacts significantly on
the validity of the translation of raw data into activity outputs and
the same rules that apply for a healthy person might not apply for
one with impairment. In the case of DM1, this study demonstrated
that an ankle-worn GENEActiv, more than a wrist-worn device, could
provide reliable and sensitive results about an ambulant DM1 patient
if the research interest is detecting walking periods, differentiating
these from standing still periods and identifying different walking
speeds. Moreover, the accelerometry results during these short func-
tional assessments correlated accurately with the severity of the con-
dition and impairment, and strength showed not to be the only
factor impacting on walking speed.
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